Gocatamig not checked

Merck & Co. · HPN328 · MK-6070

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
4 active
4 in total · 2 in the EU
Targets
 

What this is

How it works
An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
Tested for
Small Cell Lung Cancer (2 trials), Small-Cell Lung Cancer, Neuroendocrine Carcinoma, Small Cell Lung Cancer Extensive Stage
Main trialPhase 3
“Researchers are looking for new ways to treat limited-stage small cell lung cancer (LS-SCLC). LS-SCLC is a type of lung cancer that has not spread from the lung to other parts of the body. Researchers want to learn if gocatamig given with durvalumab can treat LS-SCLC. The main goal of this trial is to learn if participants who receive gocatamig with durvalumab live longer without the cancer getting worse than those who receive durvalumab alone.”In the company’s words, NCT07908537 on ClinicalTrials.gov
Other names
HPN328 · MK-6070 · DS-3280

Other drugs for Small Cell Lung Cancer

All 118 drugs for Small Cell Lung Cancer

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 8 Dec 2031 A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)
Phase 1/2Active, not recruiting 28 Jan 2028 A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Phase 1/2Recruiting 15 Feb 2029 A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Phase 1/2Recruiting 29 Nov 2030 A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Gocatamig

Following is part of Solo: you see every change to Gocatamig the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in